Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Blanch-Rubió, Josep
• dc.contributor.author Soldevila-Domenech, Natalia
• dc.contributor.author Tío, Laura
• dc.contributor.author Llorente Onaindia, Jone
• dc.contributor.author Ciria Recasens, Manuel
• dc.contributor.author Polino, Luciano
• dc.contributor.author Gurt, Alba
• dc.contributor.author Torre Fornell, Rafael de la
• dc.contributor.author Maldonado, Rafael, 1961-
• dc.contributor.author Monfort, Jordi
• dc.contributor.author The Covidmar Study Group
• dc.date.accessioned 2020-12-18T14:13:52Z
• dc.date.available 2020-12-18T14:13:52Z
• dc.date.issued 2020
• dc.description.abstract Coronavirus disease 19 (COVID-19) is currently a global pandemic that affects patients with other pathologies. Here, we investigated the influence of treatments for osteoporosis and other non-inflammatory rheumatic conditions, such as osteoarthritis and fibromyalgia, on COVID-19 incidence. To this end, we conducted a cross-sectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona, Spain). In our cohort, COVID-19 cumulative incidence from March 1 to May 3, 2020 was compared to population estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for COVID-19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were negatively associated with COVID-19 incidence. Some analgesics, particularly pregabalin and most of the studied antidepressants, were positively associated with COVID-19 incidence, whereas duloxetine presented a negative association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti-hypertensive drugs and chronic non-steroidal anti-inflammatory drugs had no effect on COVID-19 incidence in the studied population. Our results provide novel evidence to support the maintenance of the main anti-osteoporosis treatments in COVID-19 patients, which may be of particular relevance to elderly patients affected by the SARS-CoV-2 pandemic.
• dc.description.sponsorship This study was supported by Hospital del Mar. Authors funding includes “Ministerio de Ciencia, Innovación y Universidades” (#AEI-SAF2017-84060-R FEDER to R.M., #DPI2016-80283-C2-2-R), “Ministerio de Sanidad, Servicios Sociales e Igualdad” (#RD16/0017/0020 & #PNSD-2017I068 to R.M., #PI18/00059 to TCS-M) and “Generalitat de Catalunya” (#2017-SGR-669 & #ICREA- Acadèmia 2015 to R.M., #2017-SGR-138 to R.D.L.T.). N.S.D. is recipient of predoctoral fellowship #2019-DI-47 from the DIUE-AGAUR of the “Generalitat de Catalunya”.
• dc.format.mimetype application/pdf
• dc.identifier.citation Blanch-Rubió J, Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Ciria-Recasens M, Polino L, Gurt A, de la Torre R, Maldonado R, Monfort J, Group TCS. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY). 2020; 12(20):19923-37. DOI: 10.18632/aging.104117
• dc.identifier.doi http://dx.doi.org/10.18632/aging.104117
• dc.identifier.issn 1945-4589
• dc.identifier.uri http://hdl.handle.net/10230/46093
• dc.language.iso eng
• dc.publisher Impact Journals
• dc.relation.ispartof Aging (Albany NY). 2020; 12(20):19923-37
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/SAF2017-84060-R
• dc.rights © 2020 Blanch-Rubió et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/3.0/
• dc.subject.keyword COVID-19
• dc.subject.keyword Anti-resorptive drugs
• dc.subject.keyword Calcium
• dc.subject.keyword Denosumab
• dc.subject.keyword Vitamin D
• dc.subject.keyword Zoledronate
• dc.title Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion